Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2021
• Auteurs : Jean-Frédéric BlancFaiza KhemissaJean-Pierre BronowickiCarole MonterymardJean-Marc PerarnauVincent BourgeoisStéphane ObledMeher Ben AbdelghaniIsabelle Mabile-ArchambeaudRoger FarouxJean-François SeitzChristophe LocherHélène SenellartAnne-Laure VillingFranck AudemarCharlotte CostentinGaël DeplanqueSylvain ManfrediJulien EdelineEvelyne BoucherMarie TalarminSamuel Le SourdJulien VergniolAlice GagnaireLaurent BedenneJean-Louis JouvePatrick HillonCôme LepageAnne MinelloHélène BarraudThierry LecomteJean-Pierre BarbieuxPatrice WolffValérie PhoutthasangChristine BelletierIsabelle ArchambeaudTamara Matysiak BudnikMatthieu SchneeMuriel DulucEmmanuelle Norguet MonnereauJaafar BennounaSandrine HiretMichel GatineauMohamed RamdaniYann Le BricquirNathalie Ganne-CarrieValérie BourcierChristophe PiletteBarbara DauvoisMathieu BaconnierPierre MichelPhilippe ThevenetHélène Cosme-GassmannFrançois HabersetzerCamélia ColtescuMathieu PauwelsSophie Nahon BrissonneauJoëlle EgreteauJérôme DesrameDominique AubyPatrick TexereauPierre-Luc EtienneLouis-Marie DourtheYoussef Tazi
• Organismes : Centre Paul Strauss
• Publié dans Hepatology international le 02/11/2020

---

Fichiers liés : PDF Datastream.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2021
• Auteurs : Solène HebertPierre ClavelBenjamin MaierKatsuhiro MizutaniFrançois DelvoyeBertrand LapergueMalek Ben MaachaRobert FahedSimon EscalardJean-Philippe DesillesHocine RedjemGabriele CiccioStanislas SmajdaBenjamin GorySébastien RichardRaphaël BlancMichel P. PiotinMikaël Mazighi
• Organismes : Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Service Neuroradiologie diagnostique et interventionnelle [Hôpital Foch] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Service Neuroradiologie diagnostique et interventionnelle [Hôpital Foch] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Laboratoire de Recherche Vasculaire Translationnelle Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Laboratoire de Recherche Vasculaire Translationnelle Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Service de neurologie [CHRU Nancy] Laboratoire de Recherche Vasculaire Translationnelle Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Laboratoire de Recherche Vasculaire Translationnelle Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Laboratoire de Recherche Vasculaire Translationnelle Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP]
• Publié dans Journal of Stroke and Cerebrovascular Diseases le 26/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2021
• Auteurs : Pierre SenersCyril DargazanliMichel P. PiotinDenis SablotSerge BracardPhilippe NiclotJean-Claude BaronGeorgios Tsivgoulis
• Organismes : Institut de psychiatrie et neurosciences de Paris FHU NeuroVasc [Site Sainte-Anne, Paris] Centre Hospitalier Régional Universitaire [Montpellier] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier René Dubos [Pontoise] Institut de psychiatrie et neurosciences de Paris FHU NeuroVasc [Site Sainte-Anne, Paris] Institut de psychiatrie et neurosciences de Paris FHU NeuroVasc [Site Sainte-Anne, Paris]
• Publié dans Stroke le 31/10/2020

---

Résumé : Background and Purpose: Whether bridging therapy (intravenous thrombolysis [IVT] followed by mechanical thrombectomy) is superior to IVT alone in minor stroke with basilar artery occlusion remains uncertain. Methods: Multicentric retrospective observational study of consecutive minor stroke patients (National Institutes of Health Stroke Scale score ≤5) with basilar artery occlusion intended for IVT alone or bridging therapy. Propensity-score weighting was used to reduce baseline between-groups differences, and residual imbalance was addressed through adjusted logistic regression, with excellent outcome (3-month modified Rankin Scale score 0–1) as the dependent variable. Results: Fifty-seven patients were included (28 and 29 in the bridging therapy and IVT alone groups, respectively). Following propensity-score weighting, the distribution of baseline clinical and radiological variables was similar across the 2 patient groups, except age, posterior circulation Alberta Stroke Program Early CT Score, history of hypertension and smoking, and onset-to-IVT time. Compared with IVT alone, bridging therapy was associated with excellent outcome (adjusted odds ratio=3.37 [95% CI, 1.13–10.03]; P =0.03). No patient experienced symptomatic intracranial hemorrhage. Conclusions: Our results suggest that bridging therapy may be superior to IVT alone in minor stroke with basilar artery occlusion.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2021
• Auteurs : Dominique FabreJustine MouginDelphine MitilianFrederic CochennecCarlos Garcia AlonsoJean-Pierre BecqueminPascal DesgrangesEric AllaireSarah HamdiPhilippe BrenotRiyad BourkaibStephan Haulon
• Organismes : Hypertension pulmonaire : physiopathologie et innovation thérapeutique Hypertension pulmonaire : physiopathologie et innovation thérapeutique Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 Hypertension pulmonaire : physiopathologie et innovation thérapeutique IMRB - SMCD/"Senescence, Metabolism and Cardiovascular Diseases" [Créteil] Service de chirurgie thoracique et cardio-vasculaire [Mondor] IMRB - SMCD/"Senescence, Metabolism and Cardiovascular Diseases" [Créteil] Clinique Geoffroy Saint-Hilaire Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Hôpital Marie-Lannelongue Hôpital Marie-Lannelongue Centre hospitalier Saint-Joseph [Paris] Université Paris-Saclay Hypertension pulmonaire : physiopathologie et innovation thérapeutique
• Publié dans European Journal of Vascular and Endovascular Surgery le 22/10/2020

---

Fichiers liés : S1078588420310492.pdf

---

Source

---

• Type de publi. : Rapport
• Date de publi. : 01/02/2021
• Auteurs : Jean-François SoussanaClaire WeillPatrick CaronJean-Luc ChottePierre-Benoît JolyPramod AggarwalMonique AxelosImke de BoerThierry CaquetCarole CarantaPhilippe ChemineauChristine CherbutMathieu DenisJessica FanzoPatrick FlammarionJean-François GuéganChristophe C. GouelSégolène Halley Des FontainesOlivier HamantDavid HannahMarion HetheringtonChristian HuygheCyril KaoAntoine KremerPeter LangridgeDavid LeadleyMichael LeeMarcus LindnerAllison LocontoMauricio Antonio LopesValérie Masson-DelmotteAlan MatthewsRaoul MilleRobert J. NaimanRiboli ElioJohan SchotYouba SokonaAndrew StirlingDaniel ToméMaria Concetta TomeiSébastien TreyerSaskia VisserJacques WerySarah Whitmee
• Organismes : Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Université de Montpellier Institut de Recherche pour le Développement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement International Maize and Wheat Improvement Center Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Wageningen University and Research [Wageningen] Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement International Science Council John’s Hopkins Berman Institute of Bioethics Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut de Recherche pour le Développement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement University of Birmingham [Birmingham] University of Leeds Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement University of Adelaide Université Paris-Saclay Rothamsted Research European Forest Institute Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Laboratoire Interdisciplinaire Sciences, Innovations, Sociétés Brazilian Agricultural Research Corporation = Empresa Brasileira de Pesquisa Agropecuária Intergovernmental Panel on Climate Change Université Paris-Saclay Trinity College Dublin Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement University of Washington [Seattle] Imperial College London Universiteit Utrecht / Utrecht University [Utrecht] Intergovernmental Panel on Climate Change University of Sussex Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement National Research Council of Italy | Consiglio Nazionale delle Ricerche Institut du Développement Durable et des Relations Internationales Wageningen University and Research [Wageningen] International Center for Agricultural Research in the Dry Areas University of Oxford

---

Résumé : How scientists might better contribute to SDGs in the land sector? At the invitation of INRAE, a group of high-level international experts delivers a comprehensive and systemic approach.

---

Fichiers liés : Rapport processus Royaumont (17 03)-CC-BY.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/01/2021
• Auteurs : Thomas W.L. ScheerenJan BakkerThomas KaufmannDjillali AnnanePierre AsfarEvert Christiaan BoermaMaurizio CecconiMichelle S. ChewBernard CholleyMaria B. CronhjortDaniel P. de BackerArnaldo DubinMartin W. DünserJacques DuranteauAnthony C. GordonLudhmila Hajjar HajjarOlfa HamzaouiGlenn P. HernandezVanina Siham Kanoore EdulGeert KosterGiovanni LandoniMarc LeoneBruno LevyClaude MartinAlexandre MebazaaXavier MonnetAndrea MorelliDidier M. PayenRupert M. PearseMichael R. PinskyPeter L. RadermacherDaniel Arnulf ReuterYasser L. SakrMichael SanderBernd SaugelMervyn SingerPierre Alexandre SquaraAntoine Vieillard-BaronPhilippe VignonJean Louis VincentIwan C.C. van Der HorstSimon Tilma VistisenJean Louis Teboul
• Organismes : University of Groningen [Groningen] University Medical Center Groningen [Groningen] New York University Langone Medical Center Columbia University Medical Center Erasmus University Medical Center [Rotterdam] University of Groningen [Groningen] Hôpital Raymond Poincaré [AP-HP] UFR Sciences de la santé Simone Veil Centre Hospitalier Universitaire d'Angers MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale Medical Centre Leeuwarden Istituto Clinico Humanitas [Milan] Humanitas University [Milan] Linköping University Hôpital Européen Georges Pompidou [APHP] UFR Médecine [Santé] - Université Paris Cité Karolinska Institutet [Stockholm] Centre Hospitalier Interrégional Edith Cavell Universidad Nacional de la Plata [Buenos Aires] University of Linz - Johannes Kepler Universität Linz Kepler University Hospital UFR Sciences de la santé Simone Veil Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Imperial College London Universidade de São Paulo = University of São Paulo AP-HP - Hôpital Antoine Béclère [Clamart] Pontificia Universidad Católica de Chile = Pontifical Catholic University of Chile [Santiago] Hospital Juan A. Fernandez [Buenos Aires, Argentina] University Medical Center Groningen [Groningen] Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] Hôpital Nord [CHU - APHM] Défaillance Cardiovasculaire Aiguë et Chronique Hôpital Nord [CHU - APHM] Département d’Anesthésie-Réanimation-SMUR [Hôpital Lariboisière] Centre de Référence de l’Hypertension Pulmonaire Sévère [CHU Le Kremlin Bicêtre] Hypertension pulmonaire : physiopathologie et innovation thérapeutique Ecotaxie, microenvironnement et développement lymphocytaire Hôpital Lariboisière-Fernand-Widal [APHP] William Harvey Research Institute, Barts and the London Medical School Queen Mary University of London University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis] Universitätsklinikum Ulm - University Hospital of Ulm University Medical Center Rostock Universitätsklinikum Jena = Jena University Hospital [Jena, Germany] Justus-Liebig-Universität Gießen = Justus Liebig University Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] University College London [UCL] Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] Centre de recherche en épidémiologie et santé des populations Centre d'Investigation Clinique de Limoges Université libre de Bruxelles = Free University of Brussels Maastricht University Medical Centre Aarhus University Hospital Centre de Référence de l’Hypertension Pulmonaire Sévère [CHU Le Kremlin Bicêtre] Hypertension pulmonaire : physiopathologie et innovation thérapeutique
• Publié dans Annals of Intensive Care le 23/10/2020

---

Résumé : Background: Treatment decisions on critically ill patients with circulatory shock lack consensus. In an international survey, we aimed to evaluate the indications, current practice, and therapeutic goals of inotrope therapy in the treatment of patients with circulatory shock. Methods: From November 2016 to April 2017, an anonymous web-based survey on the use of cardiovascular drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 14 questions focused on the profile of respondents, the triggering factors, first-line choice, dosing, timing, targets, additional treatment strategy, and suggested effect of inotropes. In addition, a group of 42 international ESICM experts was asked to formulate recommendations for the use of inotropes based on 11 questions. Results: A total of 839 physicians from 82 countries responded. Dobutamine was the first-line inotrope in critically ill patients with acute heart failure for 84% of respondents. Two-thirds of respondents (66%) stated to use inotropes when there were persistent clinical signs of hypoperfusion or persistent hyperlactatemia despite a supposed adequate use of fluids and vasopressors, with (44%) or without (22%) the context of low left ventricular ejection fraction. Nearly half (44%) of respondents stated an adequate cardiac output as target for inotropic treatment. The experts agreed on 11 strong recommendations, all of which were based on excellent (> 90%) or good (81–90%) agreement. Recommendations include the indications for inotropes (septic and cardiogenic shock), the choice of drugs (dobutamine, not dopamine), the triggers (low cardiac output and clinical signs of hypoperfusion) and targets (adequate cardiac output) and stopping criteria (adverse effects and clinical improvement). Conclusion: Inotrope use in critically ill patients is quite heterogeneous as self-reported by individual caregivers. Eleven strong recommendations on the indications, choice, triggers and targets for the use of inotropes are given by international experts. Future studies should focus on consistent indications for inotrope use and implementation into a guideline for circulatory shock that encompasses individualized targets and outcomes.

---

Fichiers liés : 13613_2021_Article_806.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/01/2021
• Auteurs : Elise F NassifBernhard MlecnikConstance ThibaultMarie AuvrayDaniela BruniAlexandre ColauEva CompératGabriela BindeaAurélie CatteauAurélie FugonIsabelle BoquetMarine MartelPhilippe CamparoPierre ColinRoubini ZakopoulouAristotelis BamiasMostefa BennamounXavier BarthereBruno d'AcremontMarine LefevreFrançois AudenetArnaud MéjeanVirginie VerkarreStéphane OudardJérôme Galon
• Organismes : Hôpital Européen Georges Pompidou [APHP] Centre de Recherche des Cordeliers Inovarion Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Centre de Recherche des Cordeliers Groupe Hospitalier Diaconesses Croix Saint-Simon Groupe Hospitalier Diaconesses Croix Saint-Simon Centre de Recherche des Cordeliers Institut Mutualiste de Montsouris Institut Mutualiste de Montsouris Clinique Saint Jean de Dieu Institut Mutualiste de Montsouris Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Centre de Recherche des Cordeliers
• Publié dans Cancers le 21/10/2020

---

Résumé : (1) Background-The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods-This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece). Pre-treatment tumor samples were immunostained for CD3+ and CD8+ T cells and quantified to determine the IS. The results were associated with the response to neoadjuvant chemotherapy, time to recurrence (TTR), and OS. (3) Results-Low (IS-0), intermediate (IS-1-2), and high (IS-3-4) ISs were observed in 36.5, 43.7, and 19.8% of the cohort, respectively. IS was positively associated with a pathologic complete response (pCR; p-value = 0.0096). A high IS was found in 35.7% of patients with a pCR, whereas it was found in 11.3% of patients without a pCR. A low IS was observed in 48.4% of patients with no pCR and in 21.4% of patients with a pCR. Low-, intermediate-, and high-IS patients had five-year recurrence-free rates of 37.2%, 36.5%, and 72.6%, respectively. In the multivariable analysis, a high IS was associated with a prolonged TTR (high vs. low: p = 0.0134) and OS (high vs. low: p = 0.011). (4) Conclusions-This study showed the significant prognostic and predictive roles of IS regarding localized MIBC.

---

Fichiers liés : cancers-13-00494.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 28/01/2021
• Auteurs : Pierre DrossartVincent Coude Du ForestoGiovanna TinettiMarc OllivierPaul EcclestonPierre-Olivier LagageJean-Philippe BeaulieuMichel BerthéJerôme AmiauxPascale Danto
• Organismes : Institut d'Astrophysique de Paris Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics University College London [UCL] Institut d'astrophysique spatiale STFC Rutherford Appleton Laboratory Institut d'Astrophysique de Paris Centre National d'Études Spatiales [Toulouse]

---

Résumé : The ESA/Ariel mission will address some fundamental questions on the composition and formation of exoplanets, in the frame of the ESA Cosmic Vision Program. Ariel is to be launched in 2029. It will use the technique of transit spectroscopy in the near-infrared (1.1-7.8 μm), observing host stars during planetary transit or eclipses, obtained on around one thousand transiting planets. It will provide an extensive statistical study on planets from Earth-size to gas giants around a range of host star types, in complement to James Webb Space Telescope and ground-based observatories observations. The unique performances of Ariel are to record simultaneously the whole wavelength range from about 1 to 8 μm, to record up to ∼ 1000 targets for statistical purpose and to study in parallel host star activity with planetary spectra thanks to its visible channel concurrent observations. The international consortium, led by G. Tinetti (UK), will procure to ESA the instrument and subsystems, including the telescope and the spectrometers. The Ariel satellite will consist in a telescope (elliptical mirror 1100 mm x 730 mm size) with radiatively cooled optics below 60K. The telescope feeds two separate instruments : The FGS (Fine Guide Sensor), providing three photometric channels (0.5-0.6 micron ; 0.8-1.1 micron and 1.10-1.95 μm, the latter with coarse spectral resolution R ≥ 15) The AIRS (Ariel Infra-Red Spectrometer) is a two channels grating spectrometer (1.95-3.9 μm with R ≥ 100 and 3.9-7.9 μm with R ≥ 30) The exoplanet spectra are retrieved from transit and/or eclipse observations on the target with data processing including calibration of photometric/spectral science spectra, with timely public release of data to maximize science return of Ariel. Within the consortium, the French participation (co-PIs JP Beaulieu \& PO Lagage) is supported by CNES and will be in charge principally of : - 1. AIRS (Ariel infrared spectrometer) instrument o optical module (including detectors & Cold Front End Electronics) and cryoharnesses including with full calibration at detector and instrument level o AIRS instrument detector control unit t with acceptance by the AMC systems team - 2 Contribution to management and systems engineering o for the Instrument Operations and Science Data Centre (IOSDC); o contribute to algorithm, software definition, and data processing of the SGS and to the observations and scheduling. A description of the AIRS instrument is given in a companion paper(Amiaux et al. this session). In preparation of the Ariel future observations, science schools are annually organized for the training of new PhD students or post-doctoral. The first French Ariel school in 2019 has already been followed by the publication of 4 papers (ARESI, II, III, IV) References Ariel Definition Study Report ESA-SCI (2020) in press. Tinetti, Giovanna, Drossart, Pierre; Eccleston, Paul et al., A chemical survey of exoplanets with ARIEL. 2018ExA, 46, 135T Puig, Ludovic, Pilbratt, Göran, et al. The Phase A study of the ESA M4 mission candidate ARIEL. 2018ExA, 46,211P Encrenaz, Thérèse, Tinetti, G., Coustenis, A. Transit spectroscopy of temperate Jupiters with ARIEL: a feasibility study. 2018ExA, 46, 31E Edwards, Billy, Changeat, Quentin, et al. ARES I: WASP-76 b, A Tale of Two HST Spectra 2020AJ, 160, 8E Skaf, Nour, Bieger, Michelle Fabienne, et al. ARES II. Characterizing the Hot Jupiters WASP-127 b, WASP-79 b, and WASP-62b with the Hubble Space Telescope 2020AJ, 160, 109S Pluriel, William; Whiteford, Niall, et al. ARES III. Unveiling the Two Faces of KELT-7 b with HST WFC3 2020AJ, 160, 112P Gloria Guilluy, Amelie Gressier, et al. ARES IV: Probing the Atmospheres of the Two Warm Small Planets HD 106315 C and HD 3167 C with HST/WFC3 CAMERA. Submitted to AJ.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/01/2021
• Auteurs : Hanspeter NaegeliJean Louis BressonTamas DalmayIan Crawford DewhurstMichelle M EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoEwen MullinsFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiFernando ÁlvarezMichele ArdizzoneSilvia FedericiAntonio FernandezAndrea GennaroJose Ángel Gómez RuizDafni Maria KagkliAnna LanzoniFranco Maria NeriNikoletta PapadopoulouKonstantinos ParaskevopoulosTommaso RaffaelloFranz StreisslGiacomo de Sanctis
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Résumé : Soybean GMB151 was developed to confer tolerance to 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicides and resistance to nematodes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between soybean GMB151 and its conventional counterpart needs further assessment, except for palmitic acid and heptadecenoic acid in seeds and carbohydrate and crude protein in forage, which does not raise nutritional and safety concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the HPPD-4 and Cry14Ab-1 proteins as expressed in soybean GMB151, and finds no evidence that the genetic modification would change the overall allergenicity of soybean GMB151. In the context of this application, the consumption of food and feed from soybean GMB151 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that soybean GMB151 is as safe as the conventional counterpart and non-GM soybean reference varieties tested, and no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable soybean GMB151 seeds into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of soybean GMB151. The GMO Panel concludes that soybean GMB151 is as safe as its conventional counterpart and the tested non-GM soybean reference varieties with respect to potential effects on human and animal health and the environment.

---

Fichiers liés : EFSA Journal - 2021 - - Assessment of genetically modified soybean GMB151 for food and feed uses under Regulation EC No.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/01/2021
• Auteurs : Aline ClabautCéline GrareGaëlle Rolland-ValognesJean-Guillaume LetarouillyChantal BourrierThomas AndersenTanja SikjærLars RejnmarkCharlotte EjerstedPhilippe PastoureauPierre HardouinMassimo SabatiniOdile Broux
• Organismes : Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 Université du Littoral Côte d'Opale Impact de l'environnement chimique sur la santé humaine - ULR 4483 Institut de Recherches SERVIER Centre Hospitalier Régional Universitaire [CHU Lille] Institut de Recherches SERVIER Aarhus University Hospital Aarhus University Hospital Institut de Recherches SERVIER Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 Université du Littoral Côte d'Opale Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 Université du Littoral Côte d'Opale
• Publié dans PLoS ONE le 25/10/2020

---

Résumé : Our preliminary findings have lead us to propose bone marrow adipocyte secretions as new contributors to bone loss. Indeed, using a coculture model based on human bone marrow stromal cells, we previously showed that soluble factors secreted by adipocytes induced the conversion of osteoblasts towards an adipocyte-like phenotype. In this study, microarray gene expression profiling showed profound transcriptomic changes in osteoblasts following coculture and confirmed the enrichment of the adipocyte gene signature. Double immunofluorescence microscopic analyses demonstrated the coexpression of adipogenic and osteoblastic specific markers in individual cells, providing evidence for a transdifferentiation event. At the molecular level, this conversion was associated with upregulated expression levels of reprogramming genes and a decrease in the DNA methylation level. In line with these in vitro results, preliminary immunohistochemical analysis of bone sections revealed adipogenic marker expression in osteoblasts from elderly subjects. Altogether, these data suggest that osteoblast transdifferentiation could contribute to decreased bone mass upon ageing.

---

Fichiers liés : 64fa42a063a7c7d2ef364e3955bbdf2f.pdf

---

Source